Facense is developing smartglasses with small sensors on the frames that are capable of continuously and unobtrusively measuring the wearer's vital signs and emotional responses. Facense's technology enables the detection and prediction of various medical conditions, including hypertension, stroke, congestive heart failure, asthma, chronic obstructive pulmonary disease, and migraines, as well as early detection of COVID-19 symptomatic behavior.
With its continuous unobtrusive physiological monitoring, the company aims to enhance telehealth applications and provide a myriad of medical applications. Facense has an extensive IP portfolio that includes 37 granted US patents and dozens of patent applications around the world for smartglasses with sensors for wellness, telehealth, safety, and industrial applications.